This investment opportunity offers a unique chance for individuals and institutions to actively participate in the growth and transformation of the healthc...
The first patient was randomized in China in the NATiV3 Phase III clinical trial, triggering a milestone payment of $3 million from CTTQ to Inventiva.&nb...
ImpriMed, a leading precision medicine startup focused on leveraging artificial intelligence to improve cancer treatment, announced the close of a $2...
Parse Biosciences, a leading provider of easily accessible and scalable solutions for single-cell sequencing, announced today that the company has raised $...
Series A led by Sofinnova Partners and OMX Ventures Freya Biosciences, a trans-Atlantic biotech company specializing in women's health, announced today a ...
Ten projects will receive funding to help address adult immunization gaps in communities across the country GSK launched the COiMMUNITY Initiative in Ju...
Perpetual Medicines announced it has closed an $8 million seed financing to advance its integrated computational design and synthesis platform for pe...
Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, announced that its wholly owned subsidiary, O...
The oversubscribed capital raise was led by existing venture capital investors: U.S. Venture Partners, Norwest Venture Partners, InnovaHealth Partners, and...
T-Therapeutics raises £48 million Series A for development of next generation TCR therapeutics to transform cancer treatment Fundraise led by Sofin...
“The close of the LimFlow acquisition allows us to begin to integrate this exciting technology that is offering new hope to patients suffering from C...
Seven major research projects to receive more than £14 million to develop new tests, treatments and devices for neurodegenerative diseases includin...
Gero, a biotechnology company focused on aging and chronic diseases, has closed $6M in a Series A extension round. This funding round positions Gero to con...
In the first nine months of 2023, Novo Nordisk’s sales increased by 33% and operating profit increased by 37% both at CER. Profit and loss (CE...
© 2025 Biopharma Boardroom. All Rights Reserved.
